ＭＤＳ及び急性骨髄性白血病に対するビタミンＤ３（１α（ＯＨ）Ｄ３）療法

DOI Web Site PubMed

書誌事項

タイトル別名
  • Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1.ALPHA.(OH)D3).
  • MDSおよび急性骨髄性白血病に対するビタミンD3〔1α(OH)D3〕療法
  • MDS オヨビ キュウセイ コツズイセイ ハッケツビョウ ニ タイスル ビタミ

この論文をさがす

抄録

1α, 25 (OH)2D3 is known as one of the inducers of non-lymphoid leukemic cell differentiation. We present two leukemic patients and one RAEB patient treated with 1 hydroxyvitamin D3 [1α (OH) D3] which is converted in vivo to active metabolite of vitamin D3, 1α, 25 (OH)2D3 by liver cells. Case 1 is 77-year-old woman with AML (M1) who has complications of severe cholelithiasis. Case 2 is 47-year-old man with RAEB. Case 3 is 58-year-old man with hypoplastic leukemia AML (M2).<br>We have also investigated in vitro effects of 1α, 25 (OH)2D3 on leukemic cells isolated freshly from the bone marrow of these three patients. After incubation with 1α, 25 (OH)2D3, the number of adherent cells on the bottom of Petri dish has increased, and those cells have become morphologically quite similar to monocytemacrophage.<br>These three patients have been administered 4.5-15μg/day of 1α (OH) D3 by mouth. Administration of 1α (OH) D3 has had an effect on abating leukemic cells in bone marrow of these three patients and the dispersed chromatin of leukemic cells has aggregated as heterochromatin. In case 1, atypical lymphocyte-like cells have appeared, which were considered to be differentiated from leukemic cells. In case 3, pancytopenia of peripheral blood has improved.<br>As an adverse effect of 1α (OH) D3 therapy, hypercalcemia occurred in case 1. However, after discontinuation of drug, hypercalcemia disappeared and the level of serum calcium returned to normal range within three days.

収録刊行物

  • 臨床血液

    臨床血液 28 (6), 830-838, 1987

    一般社団法人 日本血液学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ